Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

ResMed Inc. Common Stock (NY:RMD)

214.44 +0.36 (+0.17%)
Official Closing Price Updated: 7:00 PM EDT, Apr 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about ResMed Inc. Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Benzinga's Top Ratings Upgrades, Downgrades For January 17, 2023
Via Benzinga
Where ResMed Stands With Analysts
ResMed (NYSE:RMD) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Competitor Recall Continues To Show Opportunities For ResMed
Via Benzinga
Looking Into ResMed's Return On Capital Employed
According to Benzinga Pro, during Q1, ResMed (NYSE:RMD) earned $210.48 million, a 7.9% increase from the preceding quarter. ResMed also posted a total of $950.29 million in sales, a 3.89% increase... 
Via Benzinga
Company Report Roundup: Tesla, Tractor Supply, American Express, and More
Plus a look at investing books, stocks to watch, and other topics for investors. 
Via The Motley Fool
Silk Road Medical Stock Scores Relative Strength Rating Upgrade
Silk Road Medical sees its Relative Strength Rating reach the elite 90-plus level. 
Via Investor's Business Daily
Hopeful Golden Cross Forms On ResMed's Chart
If history is any guide, there may be good fortune ahead for shares of ResMed (NYSE:RMD). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock. 
Via Benzinga
Earnings Scheduled For August 11, 2022
Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million. 
Via Benzinga
Analyst Ratings for ResMed
Analysts have provided the following ratings for ResMed (NYSE:RMD) within the last quarter: 
Via Benzinga
ResMed's Q3 Earnings Short Of Expectations, Profit Margins Contract
Via Benzinga
Earnings Scheduled For October 27, 2022
Companies Reporting Before The Bell • Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2022
Upgrades 
Via Benzinga
Tuesday Is Your Last Chance To Buy ResMed Before The Dividend Payout
  Tuesday marks the last chance for investors to receive the next dividend payout from ResMed (NYSE:RMD). 
Via Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $3,400 Today
ResMed (NYSE:RMD) has outperformed the market over the past 20 years by 11.43% on an annualized basis producing an average annual return of 19.33%. Currently, ResMed has a market capitalization of... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2022
Upgrades 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 12, 2022
  
Via Benzinga
How Is The Market Feeling About ResMed?
ResMed's (NYSE:RMD) short percent of float has fallen 6.8% since its last report. The company recently reported that it has 1.39 million shares sold short, which is 0.96% of all... 
Via Benzinga
Semiconductor Shortages - See How ResMed Is Tackling
ResMed Inc (NYSE: RMD) has redesigned the AirSense 10 to eliminate a short-supply semiconductor chipset used for cellular communications chips.  
Via Benzinga
Here's How Much $1000 Invested In ResMed 10 Years Ago Would Be Worth Today
ResMed (NYSE:RMD) has outperformed the market over the past 10 years by 10.69% on an annualized basis producing an average annual return of 21.91%. Currently, ResMed has a market capitalization of... 
Via Benzinga
Peering Into ResMed's Recent Short Interest
ResMed's (NYSE:RMD) short percent of float has risen 14.44% since its last report. The company recently reported that it has 1.50 million shares sold short, which is 1.03% of all... 
Via Benzinga
7 Growth Stocks to Buy in July 2022
The severe macroeconomic climate has led investors toward defensive plays, creating buy opportunities in the following growth stocks. 
Via InvestorPlace
Analyzing ResMed's Short Interest
ResMed's (NYSE:RMD) short percent of float has risen 5.62% since its last report. The company recently reported that it has 1.36 million shares sold short, which is 0.94% of all... 
Via Benzinga
Here's How Much You Would Have Made Owning ResMed Stock In The Last 15 Years
ResMed (NYSE:RMD) has outperformed the market over the past 15 years by 9.9% on an annualized basis producing an average annual return of 16.19%. Currently, ResMed has a market capitalization of $29.81... 
Via Benzinga
ResMed Strengthens Its Out-Of-Hospital Software Solutions Position With Latest Acquisition - Read How
Via Benzinga
10 Biggest Price Target Changes For Monday
Citigroup cut PVH Corp. (NYSE: PVH) price target from $94 to $73. PVH shares fell 0.7% to close at $71.96 on Friday. 
Via Benzinga
A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street
Pre-open movers U.S. stock futures traded higher in early pre-market trade after the Nasdaq tumbled over 300 points in the previous session despite better-than-expected jobs report for May. 
Via Benzinga
If You Invested $100 In Resmed 5 Years Ago, Here's How Much You Would Have Today
ResMed (NYSE:RMD) has outperformed the market over the past 5 years by 12.16% on an annualized basis producing an average annual return of 23.39%. Currently, ResMed has a market capitalization of... 
Via Benzinga
ResMed Earnings Perspective: Return On Invested Capital
Pulled from Benzinga Pro data, ResMed (NYSE:RMD) posted Q3 earnings of $179.01 million, an increase from Q2 of 11.27%. Sales dropped to $864.50 million, a 3.39% decrease between quarters. 
Via Benzinga
What 3 Analyst Ratings Have To Say About ResMed
Over the past 3 months, 3 analysts have published their opinion on ResMed (NYSE:RMD) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's... 
Via Benzinga
Earnings Outlook For ResMed
ResMed (NYSE:RMD) is set to give its latest quarterly earnings report on Thursday, 2022-04-28. Here's what investors need to know before the announcement. Analysts estimate that ResMed will report an... 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.